|No.8 Jinshun Road Zhuqiao Pudong New District,Shanghai,Chinafirstname.lastname@example.org|
|Place of Origin:||China|
|Minimum Order Quantity:||10vials or 10g|
|Delivery Time:||1-2 works day|
|Payment Terms:||, MoneyGram, L/C, T/T, D/A, D/P|
|Supply Ability:||100kg per month|
|Cas:||CAS 79561-22-1||Name:||Alarelin Acetate|
pharmaceutical grade peptides,
Deslorelin Acetate Description
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials
Recommended dosage:intravenous injection of 0.75 mg/kg before PCI, immediately after intravenous infusion of 1.75 mg/kg/h to the completion of surgery (not more than 4 hours). After 5 minutes of intravenous injection, the activated clotting time (ACT) should be monitored. If necessary, a 0.3 mg/kg dose is injected intravenously. 4 hours later, if necessary, then instilled at a low dose of 0.2 mg/kg/h for no more than 20 hours. If Replace-2 clinical trials appear (see clinical trials), they can be combined with glycoprotein IIb/IIIa inhibitor (GPI). For patients with HIT/HITTS, PCI was injected intravenously for 0.75 mg/kg and then intravenously for 1.75 mg/kg/h during PCI. It is recommended that Bivalirudin and Aspirin should be used together (300-325 mg per day).
Contact Person: Qin